目的 對(duì)東南大學(xué)醫(yī)學(xué)院附屬南京胸科醫(yī)院（南京市胸科醫(yī)院）門診結(jié)核患者口服保肝藥的使用情況和變化趨勢(shì)進(jìn)行分析，為臨床合理用藥提供依據(jù)。方法 調(diào)取南京市胸科醫(yī)院2014年1月-2015年12月門診結(jié)核患者的保肝藥使用數(shù)據(jù)，進(jìn)行統(tǒng)計(jì)和分析。結(jié)果 2014-2015年門診結(jié)核患者口服保肝藥銷售總金額略有上升，變化不大。各類保肝藥構(gòu)成比基本不變，排序相同，依次是保肝降酶藥、其他保肝中成藥、水飛薊類、保肝抗炎藥、保肝解毒藥、肝細(xì)胞膜保護(hù)劑。而保肝降酶類藥的銷售金額幾乎占了所有保肝藥銷售金額的一半。年增長(zhǎng)率最高的是保肝抗炎藥，增長(zhǎng)30%。銷售金額和使用例次排名前6位分別為雙環(huán)醇片、水飛薊賓葡甲胺片、水飛薊賓膠囊、甘草酸二銨腸溶膠囊、復(fù)方甘草酸苷膠囊和九味肝泰膠囊，而雙環(huán)醇片的銷售金額、使用例次和每例平均金額均排名第一。結(jié)論 南京市胸科醫(yī)院保肝藥的使用結(jié)構(gòu)基本合理，但尚存在某些藥物銷量異常的現(xiàn)象，需進(jìn)一步規(guī)范臨床應(yīng)用，確保結(jié)核患者保肝藥用藥安全。

Objective To analyze the use and tendency of liver protectants in outpatients with tuberculosis in Nanjing Chest Hospital Affiliated to Medical College of Southeast University (Nanjing Chest Hospital) so as to provide a reference for rational clinical use of these drugs. Method The data of liver protectants in Nanjing Chest Hospital from January 2014 to December 2015 were collected and analyzed statistically. Results From 2014 to 2015, the consumption sum of liver protectants increased slightly year by year. There was no significant change in the proportion of consumption sum of liver protectants each year, and the proportion rank (from high to low) were hepatoprotective enzyme reduction medicines, hepatoprotective Chinese patent medicines, silymarins, hepatoprotective anti-inflammatory drugs, hepatoprotective detoxification drugs, and liver cell membrane protective agents. The consumption sum of hepatoprotective enzyme reduction medicine accounted for almost half of all drug sales amounts. The annual growth rate of hepatoprotective anti-inflammatory drugs was the highest (30%). Both consumption sum and use case ranking from high to low were Bicyclol Tablets, Silybin Meglumine Tablets, Silymarin Capsules, G]yeyrrhizin Diamine Enteric-coated Capsules, Compound Glycyrrhizin Capsules, and Jiuwei Gantai Capsules. The consumption sum, use case ranking, and average cost per case of Bicyclol Tablets ranked first. Conclusion The utilization of liver protectants is basically reasonable in Nanjing Chest Hospital, but there are some degree phenomena of irrational, which still needs to be further standardized to ensure patient medication safety.